Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Nephrin, a transmembrane protein on the glomerular podocyte membrane, is an important structural molecule in the podocyte fissure membrane. Recently, it has been found that the tyrosine residue in the inner segment of Nephrin molecule is activated by the tyrosine kinase fyn (a member of the Src kinase family) to activate downstream signaling molecules to form a signal transduction pathway specific to podocytes, such as nephrin-podocin-MAPK-AP-1, nephrin-CD2AP-PI3K-Akt/PKB, nephrin-Nck-Rac/CDC42. These signaling pathways are involved in the regulation of many important physiological and pathological processes such as podocyte embryogenesis, cell survival and cytoskeletal reorganization. Similarly, the expression of nephrin protein and mRNA is also regulated by many factors.
Distribution of Nephrin
The glomerular podocyte fissure diaphragm (GPSD) is the key structure to maintain the integrity of the glomerular filtration barrier structure. In 1998, a new human gene NPHS1 was cloned in the process of studying Finnish congenital nephrotic syndrome (CNF). The in-situ hybridization technique was used to determine that its expression product was specifically localized to GPSD, so it was named Nephrin.
Nephrin belongs to the immunoglobulin superfamily molecule and is a transmembrane protein. Human Nephrin is 1241 amino acid residues long, including intracellular domain, transmembrane domain and extracellular domain. Nephrin interacts with other cleavage protein factors podocin, CD2 associated protein (CD2AP), and actinin-4 to form a major component of the glomerular filtration barrier, which plays a key role in highly specific podocyte function. In addition, the Nephrin polyprotein complex also includes cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrin, etc.
Figure 1. The proposed schematic model illustrating the molecular basis of Nephrin/MAGI1 interaction in slit diaphragm assembly and signaling. (Zhuangfeng Weng, et al. 2018)
Western blotting was used to detect human heart, brain, lung, liver, muscle, kidney, pancreas and placental tissues, and it was found that only fetal and adult kidney tissues had nephrin mRNA expression. The in-situ hybridization method was used to detect the fetal kidney tissue. It was found that only the glomerulus had the expression of Nephrin mRNA, and its distribution was similar to that of the visceral epithelial cells. Immunofluorescence electron microscopy was performed using the recombinantly expressed Nephrin N-terminal fragment as an antigen. It was confirmed that Nephrin was only distributed in the fissure membrane between the splanchnic epithelial cell foot processes, which proved that Nephrin is a structural component of the fissure membrane.
Nephrin and Kidney Disease
The clinical features of chronic nephritic syndrome (CNS) are a large number of proteinuria in the fetus, an autosomal recessive kidney disease characterized by a placental weight of more than 25% of body weight and obvious edema at birth. CNS is high in Finland and is called the Finnish CNS (CNF). The incidence rate in newborns is 1/8200. The disease progresses progressively and usually dies within 2 years of age. The only treatment is kidney transplantation. However, due to the presence of anti-Nephrin antibodies, kidney transplants tend to recur after treatment. Most of the genetic mutations in CNF have been identified, which provides a specific means for prenatal diagnosis of CNF. The genetic variation of CNF was dominated by two mutations of NPHS1, Finmajor and Finminor, accounting for 97%.
The pathological feature of membranous nephropathy (MN) is the diffuse immune complex deposition of the glomerular basement membrane (GBM) with diffuse thickening of the basement membrane. Studies have shown that patients with membranous nephropathy also have loss of podocyte barrier function and a significant decrease in the expression of Nephrin. After the podocyte cytoskeleton-actin damage, Nephrin is re-modified and exfoliated outside the cell, and α-Nephrin fragments can be detected in the urine. In the study of graft-anti-host immune rejection, cell transplantation was performed between two strains of mice, antibody against Nephrin was detected by antibody sandwich method and Nephrin and IgG immunoprecipitate were co-existed in GBM by laser confocal microscopy.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.